



September 23, 2025

To,  
Listing/ Compliance Department  
**BSE LTD.**  
Pheroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai - 400 001  
**SCRIP CODE: 543748**

To,  
Listing/ Compliance Department  
**National Stock Exchange of  
India Limited**  
“Exchange Plaza”, Plot No. C/1,  
G Block, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**SYMBOL: AARTIPHARM**

Dear Sir/Madam,

**Sub: Investor Presentation**  
**Ref: Regulation 30 of the SEBI (LODR)  
Regulations 2015**

---

Please find enclosed herewith presentation made to the Shareholders of the Company at the **6<sup>th</sup> Annual General Meeting** held on Monday, September 22, 2025.

Please take the same on your records.

Thanking you,

Yours faithfully,  
**For AARTI PHARMALABS LIMITED**

Jeevan Mondkar  
**COMPANY SECRETARY AND LEGAL HEAD**  
ICSI M. NO. A22565

Encl. a/a.

---

**AARTI PHARMALABS LIMITED**

[www.aartipharmalabs.com](http://www.aartipharmalabs.com) | CIN : L24100GJ2019PLC110964 | Email : [info@aartipharmalabs.com](mailto:info@aartipharmalabs.com)


Admin Office : 204, Udyog Kshetra, 2nd Floor, Mulund - Goregaon Link Road, Mulund (W), Mumbai, PIN - 400 080, Maharashtra, INDIA, T : +91 22 67976666 | F : +91 22 25653234  
Regd. Office : Plot No. 22-C/1 & 22-C/2, 1st Phase, G.I.D.C., Vapi 396 195, District - Valsad, Gujarat, INDIA, T : +91 260 2400467, +91 99099 94655



# 6<sup>th</sup> Annual General Meeting

SEP 2025

## 25 Years of Pharmaceutical Excellence



**220+** Products



**6** Manufacturing Units  
**3** USFDA Units



**15-20%** Global Market Share in Xanthine



**500+** Global Clients



**2,100+** Employees



**0.19x** Net Debt/Equity



**3**

State-of-the-art R&D facilities



**50** US DMF  
**31** CEP



**A+** Credit rating




SCIENCE  
BASED  
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION


# COMPANY OVERVIEW




- Aarti Pharmalabs Limited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 130+ bn (FY25)
- Globally recognized manufacturer of generic API, Xanthine derivatives and a leading player in CDMO/CMO services
- Demonstrated strong expertise in development of robust & cost-effective process for rapid scale up and commercial production
- Received accreditation from several agencies, including USFDA, EU GMP, EDQM (European Pharmacopoeia), KFDA (Korea), and COFEPRIS (Mexico)
- Strategically located in western India with proximity to ports




STANDALONE REVENUE (INR Mn)  
& EBITDA MARGINS (%)



GEOGRAPHICAL SALES (FY25)




# KEY MILESTONES



# KEY BUSINESS SEGMENTS

## QUARTERLY REVENUE BREAK-UP



# ANNUAL CONSOLIDATED INCOME STATEMENT



PARTICULARS (INR Mn)	FY25	FY24	Y-O-Y
<b>Operational Revenue</b>	<b>21,151</b>	<b>18,526</b>	<b>14.2%</b>
Operating Expenses	16,507	14,666	12.6%
<b>EBITDA</b>	<b>4,644</b>	<b>3,860</b>	<b>20.3%</b>
<b>EBITDA Margin (%)</b>	<b>21.96%</b>	<b>20.84%</b>	<b>112 Bps</b>
Depreciation and Amortisation	869	732	18.7%
Finance costs	269	172	56.4%
Other Income	101	49	NA
<b>PBT</b>	<b>3,607</b>	<b>3,005</b>	<b>20.0%</b>
Tax Expense	883	836	5.6%
<b>PAT</b>	<b>2,724</b>	<b>2,169</b>	<b>25.6%</b>
<b>PAT Margin (%)</b>	<b>12.88%</b>	<b>11.71%</b>	<b>117 Bps</b>
Other Comprehensive Income	(98)	(4)	NA
<b>Total Comprehensive Income</b>	<b>2,626</b>	<b>2,165</b>	<b>21.3%</b>
Diluted EPS	30.04	23.93	25.5%

# HISTORICAL CONSOLIDATED INCOME STATEMENT



PARTICULARS (INR Mn)	9M-FY22	FY23	FY24	FY25
<b>Operational Revenue</b>	<b>11,999</b>	<b>19,452</b>	<b>18,526</b>	<b>21,151</b>
Total Expenses	9,929	16,031	14,666	16,507
<b>EBITDA</b>	<b>2,070</b>	<b>3,421</b>	<b>3,860</b>	<b>4,644</b>
<b>EBITDA Margins (%)</b>	<b>17.25%</b>	<b>17.59%</b>	<b>20.84%</b>	<b>21.96%</b>
Depreciation and Amortisation	421	625	732	869
Finance costs	120	211	172	269
Other Income	25	23	49	101
<b>PBT</b>	<b>1,554</b>	<b>2,608</b>	<b>3,005</b>	<b>3,607</b>
Tax	331	673	836	883
<b>PAT</b>	<b>1,223</b>	<b>1,935</b>	<b>2,169</b>	<b>2,724</b>
<b>PAT Margins (%)</b>	<b>10.19%</b>	<b>9.95%</b>	<b>11.71%</b>	<b>12.88%</b>
Other Comprehensive Income	70	(35)	(4)	(98)
<b>Total Comprehensive Income</b>	<b>1,293</b>	<b>1,900</b>	<b>2,165</b>	<b>2,626</b>
Diluted EPS (INR)	13.49	21.35	23.93	30.04

# ANNUAL STANDALONE INCOME STATEMENT








PARTICULARS (INR Mn)	FY25	FY24	Y-O-Y
<b>Operational Revenue</b>	<b>17,714</b>	<b>15,021</b>	<b>17.9%</b>
Operating Expenses	13,449	11,560	16.3%
<b>EBITDA</b>	<b>4,265</b>	<b>3,461</b>	<b>23.2%</b>
<b>EBITDA Margin (%)</b>	<b>24.08%</b>	<b>23.04%</b>	<b>104 Bps</b>
Depreciation and Amortisation	791	660	19.8%
Finance costs	256	166	54.2%
Other Income	145	110	31.8%
<b>PBT</b>	<b>3,363</b>	<b>2,745</b>	<b>22.5%</b>
Tax Expense	790	738	7.0%
<b>PAT</b>	<b>2,573</b>	<b>2,007</b>	<b>28.2%</b>
<b>PAT Margin (%)</b>	<b>14.53%</b>	<b>13.36%</b>	<b>117 Bps</b>
Other Comprehensive Income	(51)	1	NA
<b>Total Comprehensive Income</b>	<b>2,522</b>	<b>2,008</b>	<b>25.6%</b>
Diluted EPS	28.38	22.14	28.2%

# HISTORICAL STANDALONE INCOME STATEMENT



PARTICULARS (INR Mn)	9M-FY22	FY23	FY24	FY25
<b>Operational Revenue</b>	9,410	15,112	15,021	17,714
Total Expenses	7,613	12,028	11,560	13,449
<b>EBITDA</b>	1,797	3,084	3,461	4,265
<b>EBITDA Margins (%)</b>	19.10%	20.41%	23.04%	24.08%
Depreciation and Amortisation	372	558	660	791
Finance costs	113	205	166	256
Other Income	25	13	110	145
<b>PBT</b>	1,337	2,334	2,745	3,363
Tax	270	617	738	790
<b>PAT</b>	1,067	1,717	2,007	2,573
<b>PAT Margins (%)</b>	11.34%	11.36%	13.36%	14.53%
Other Comprehensive Income	71	(7)	1	(51)
<b>Total Comprehensive Income</b>	1,138	1,710	2,008	2,522
Diluted EPS (INR)	11.78	18.95	22.14	28.38

# CONSOLIDATED FINANCIAL HIGHLIGHTS





**THANK YOU**

AARTI PHARMLABS LIMITED